The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Zanubrutinib granted priority review by the FDA for the treatment of adult patients with R/R MZL
On May 19, 2021, the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug application for zanubrutinib for the treatment of adult patients with relapsed or refractory marginal zone lymphoma. The application for the Bruton’s tyrosine kinase inhibitor also received priority review. Treatment criteria indicate that patients must have received previous treatment with ≥1 CD20-directed therapy.
The application was based on clinical data from the phase II MAGNOLIA trial, which you can read more about here. A decision on the status of the application is due by September 2019.
Zanubrutinib previously received approval by the FDA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content